BIOGEN INC. Research and Development Expense
BIOGEN INC. (BIIB) reported Research and Development Expense of $284.34 million for the 3-month period ending 2013-03-31, per its 10-Q filed 2013-04-25.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2013-04-25
- BIOGEN INC. research and development expense for the quarter ending 2013-03-31 was $284.34M, a 20.12% decline year-over-year.
- BIOGEN INC. research and development expense for the quarter ending 2012-12-31 was $345.18M, a 1.84% increase year-over-year.
- BIOGEN INC. research and development expense for the quarter ending 2012-09-30 was $304.22M, a 0.94% increase year-over-year.
- BIOGEN INC. research and development expense for the quarter ending 2012-06-30 was $329.56M, a 15.37% increase year-over-year.
- BIOGEN INC. research and development expense for fiscal 2012 was $1.33B, a 9.46% increase from fiscal 2011.
- BIOGEN INC. research and development expense for fiscal 2011 was $1.22B, a 2.32% decline from fiscal 2010.
- BIOGEN INC. research and development expense for fiscal 2010 was $1.25B, a 2.69% decline from fiscal 2009.
- BIOGEN INC. research and development expense for fiscal 2009 was $1.28B, a 19.68% increase from fiscal 2008.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2013-03-31 | $284.34M 10-Q · filed 2013-04-25 | $629.52M derived: sum of 2 quarters · filed 2013-04-25 | $933.74M derived: sum of 3 quarters · filed 2013-04-25 | $1.26B derived: sum of 4 quarters · filed 2013-04-25 |
| 2012-12-31 | $345.18M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-05 | $649.40M derived: sum of 2 quarters · filed 2013-02-05 | $978.96M derived: sum of 3 quarters · filed 2013-02-05 | $1.33B 10-K · filed 2013-02-05 |
| 2012-09-30 | $304.22M 10-Q · filed 2012-10-25 | $633.78M derived: sum of 2 quarters · filed 2012-10-25 | $989.74M 10-Q · filed 2012-10-25 | $1.33B derived: sum of 4 quarters · filed 2013-04-25 |
| 2012-06-30 | $329.56M 10-Q · filed 2012-07-24 | $685.52M 10-Q · filed 2012-07-24 | $1.02B derived: sum of 3 quarters · filed 2013-04-25 | $1.33B derived: sum of 4 quarters · filed 2013-04-25 |
| 2012-03-31 | $355.96M 10-Q · filed 2013-04-25 | $694.90M derived: sum of 2 quarters · filed 2013-04-25 | $996.29M derived: sum of 3 quarters · filed 2013-04-25 | $1.28B derived: sum of 4 quarters · filed 2013-04-25 |
| 2011-12-31 | $338.93M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-05 | $640.33M derived: sum of 2 quarters · filed 2013-02-05 | $925.97M derived: sum of 3 quarters · filed 2013-02-05 | $1.22B 10-K · filed 2013-02-05 |
| 2011-09-30 | $301.39M 10-Q · filed 2012-10-25 | $587.03M derived: sum of 2 quarters · filed 2012-10-25 | $880.67M 10-Q · filed 2012-10-25 | $1.17B derived: sum of 4 quarters · filed 2013-02-05 |
| 2011-06-30 | $285.64M 10-Q · filed 2012-07-24 | $579.28M 10-Q · filed 2012-07-24 | $870.12M derived: sum of 3 quarters · filed 2013-02-05 | $1.19B derived: sum of 4 quarters · filed 2013-02-05 |
| 2011-03-31 | $293.63M 10-Q · filed 2012-05-01 | $584.48M derived: sum of 2 quarters · filed 2013-02-05 | $903.53M derived: sum of 3 quarters · filed 2013-02-05 | $1.24B derived: sum of 4 quarters · filed 2013-02-05 |
| 2010-12-31 | $290.85M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-05 | $609.90M derived: sum of 2 quarters · filed 2013-02-05 | $941.57M derived: sum of 3 quarters · filed 2013-02-05 | $1.25B 10-K · filed 2013-02-05 |
| 2010-09-30 | $319.05M 10-Q · filed 2011-10-28 | $650.73M derived: sum of 2 quarters · filed 2011-10-28 | $957.76M 10-Q · filed 2011-10-28 | $1.24B derived: sum of 4 quarters · filed 2012-02-03 |
| 2010-06-30 | $331.68M 10-Q · filed 2011-07-26 | $638.71M 10-Q · filed 2011-07-26 | $921.79M derived: sum of 3 quarters · filed 2012-02-03 | $1.23B derived: sum of 4 quarters · filed 2012-02-03 |
| 2010-03-31 | $307.03M 10-Q · filed 2011-04-21 | $590.11M derived: sum of 2 quarters · filed 2012-02-03 | $894.17M derived: sum of 3 quarters · filed 2012-02-03 | $1.31B derived: sum of 4 quarters · filed 2012-02-03 |
| 2009-12-31 | $283.08M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-03 | $587.14M derived: sum of 2 quarters · filed 2012-02-03 | $1.00B derived: sum of 3 quarters · filed 2012-02-03 | $1.28B 10-K · filed 2012-02-03 |
| 2009-09-30 | $304.06M 10-Q · filed 2010-10-26 | $720.51M derived: sum of 2 quarters · filed 2010-10-26 | $999.99M 10-Q · filed 2010-10-26 | $1.29B derived: sum of 4 quarters · filed 2011-02-04 |
| 2009-06-30 | $416.45M 10-Q · filed 2010-07-20 | $695.93M 10-Q · filed 2010-07-20 | $988.70M derived: sum of 3 quarters · filed 2011-02-04 | $1.26B derived: sum of 4 quarters · filed 2011-02-04 |
| 2009-03-31 | $279.48M 10-Q · filed 2010-04-20 | $572.25M derived: sum of 2 quarters · filed 2011-02-04 | $841.04M derived: sum of 3 quarters · filed 2011-02-04 | $1.09B derived: sum of 4 quarters · filed 2011-02-04 |
| 2008-12-31 | $292.77M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-04 | $561.57M derived: sum of 2 quarters · filed 2011-02-04 | $813.83M derived: sum of 3 quarters · filed 2011-02-04 | $1.07B 10-K · filed 2011-02-04 |
| 2008-09-30 | $268.80M 10-Q · filed 2009-10-21 | $521.06M derived: sum of 2 quarters · filed 2009-10-21 | $779.29M 10-Q · filed 2009-10-21 | |
| 2008-06-30 | $252.26M 10-Q · filed 2009-07-17 | $510.49M 10-Q · filed 2009-07-17 | ||
| 2007-12-31 | $925.16M 10-K · filed 2010-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |